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Background: Immunotherapy has been extensively pursed as a promising strategy for the treatment of cancer.
Pattern-recognition receptors (PRRs) play important roles in triggering activation of innate and adaptive immunity.
Therefore, agents that stimulate PRRs could be useful for cancer immunotherapy. We developed two kinds of X-shaped
double-stranded oligodeoxynucleotides (X-DNA), a single unit of X-DNA (XS-DNA) composed of four strands of DNA
and a ligated X-DNA complex (XL-DNA) formed by crosslinking each XS-DNA to the other, and investigated if they had
immunostimulatory activity and could be applied to anti-cancer immunotherapy.
Methods: Activation of MAPKs and NF-κB was determined by immunoblotting in bone marrow-derived primary
dendritic cells (BMDCs). Immune cytokines and co-stimulatory molecules were measured by ELISA and flow cytometry
analysis. Anti-cancer efficacy was examined in an azoxymethane/dextran sulfate sodium-induced colitis-associated
colon cancer mouse model. Association of X-DNA and TLR9 was determined by co-immunoprecipitation followed by
immunoblotting. The involvement of TLR9 and inflammasomes was determined using TLR9- or caspase-1-deficient
BMDCs. Inflammasome activation was examined by degradation of pro-caspase-1 to caspase-1 and cleavage of
pro-IL-1β to IL-1β in BMDCs.
Results: XL-DNA and XS-DNA induced activation of MAPKs and NF-κB and production of immune cytokines and
co-stimulatory molecules in BMDCs. BMDCs stimulated by XL-DNA induced differentiation of naïve CD4
+ T cells to
TH1 cells. Intravenous injection of XL-DNA into mice resulted in increased serum IFN-γ and IL-12 levels, showing
in vivo efficacy of XL-DNA to activate TH1 cells and dendritic cells. XL-DNA greatly enhanced the therapeutic efficacy of
doxorubicin, an anti-cancer drug, in colitis-associated colon cancer. XL-DNA directly associated with TLR9. In addition,
immunostimulatory activities of X-DNA were abolished in TLR9-deficient dendritic cells. Furthermore, X-DNA induced
caspase-1 degradation and IL-1β secretion in BMDCs, which were abolished in caspase-1-deficient cells.
Conclusions: X-DNA induced the activation of dendritic cells as shown by the expression of immune-cytokines
and co-stimulatory molecules, resulting in the differentiation of TH1 cells, mediated through dual activation of
TLR9 and inflammasomes. X-DNA represents a promising immune adjuvant that can enhance the therapeutic
efficacy of anti-cancer drugs by activating PRRs.
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Certain tumor cells, including lymphoma, skin, and cer-
vical tumors, survive the host defense system by evading
immune surveillance [1,2]. Cancer immunotherapy
strengthens the host immune system to fight against can-
cer, making it a promising approach for cancer treatment.
Pattern recognition receptors such as Toll-like receptors
(TLRs) expressed on innate immune cells initiate immune
responses by activating innate and adaptive immune cells
through recognition of pathogen-associated molecular
patterns (PAMPs) derived from infectious bacteria and vi-
ruses [3]. In addition to PAMPs, danger signals, namely
damage-associated molecular patterns (DAMPs) derived
from damaged cells and tissues, activate PRRs to trigger
immune responses for proper repair processes [4,5]. In
particular, PRRs respond to endogenous substances from
tumor cells and stress ligands expressed on the surface of
tumor cells, activating host immune responses as a pro-
tective defense mechanism against the developing tumor
[6,7]. The expression of co-stimulatory molecules and
immune cytokines in innate immune cells is critical to
induce the activation of adaptive immune cells [3]. Co-
stimulatory molecules interact with CD28 that is constitu-
tively expressed on the surface of naïve CD4 positive T
cells, leading to T cell proliferation and the production of
cytokines and adhesion molecules [8]. IL-12 secreted by
antigen presenting cells induces differentiation of naïve
CD4 positive T cells (TH cells) to TH1 effector cells. TH1
cells enhance the cytolytic functions of cytotoxic T cells
and natural killer cells (NK cells) [9]. In addition, IFN-γ
produced by TH1, cytotoxic T, and NK cells exerts anti-
viral, immune-regulatory, and anti-tumor properties [10].
Therefore, activation of the innate and adaptive immune
systems has become the focus of effective strategies for
cancer immunotherapy.
Development of immunostimulatory DNA assemblies
has increased the possibility for pharmaceutical and bio-
medical applications and drawn a great deal of attention
for the development of cancer immunotherapy [11].
CpG oligodeoxynucleotides (CpG ODN) have been ac-
tively explored for therapeutic purposes due to their
immunostimulatory activity [12]. CpG ODN is a short
single-stranded synthetic DNA molecule that contains a
cytosine triphosphate deoxynucleotide followed by a
guanine triphosphate deoxynucleotide. CpG ODN activates
TLR9, inducing the expression of immune cytokines and
stimulating innate and adaptive immune responses [13].
TLR9 is a type I transmembrane receptor localized on
endosomes, thereby recognizing DNA with CpG motifs de-
rived from phagocytized bacteria and viruses. Understand-
ing of the TLR9 signal cascade has prompted the clinical
development of TLR9 agonists to treat cancer as well as in-
fectious diseases, asthma, and allergies [12]. TLR9 agonists
such as CpG ODN enhance antitumor T-cell responseswhen used as an adjuvant for anti-cancer therapy [14].
There have been attempts to develop more efficient immu-
nostimulatory DNA. Roberts et al. reported that longer
DNA molecules are taken up more efficiently by cells than
shorter ones [15]. Immunostimulatory activity is enhanced
by complexing CpG ODN into a Y-shaped form compared
with single-stranded or double-stranded ODN [16]. Fur-
thermore, highly structured double-stranded DNA can be
useful as a drug delivery system. For example, doxorubicin,
an anti-cancer drug, can be intercalated into plasmid DNA
and delivered to metastatic colonies of colon carcinoma
cells in the mouse liver [17,18]. Thus, the development of
newly designed DNA assemblies may extend potential
pharmaceutical applications.
We previously described the development of X-shaped
double-stranded oligodeoxynucleotides (X-DNA) for
possible biomedical applications [11]. A single unit of
the X-DNA (XS-DNA) has an X-shaped structure com-
posed of four strands of oligodeoxynucleotides. We also
constructed a ligated X-DNA complex (XL-DNA) by cross-
linking X-DNAs by introducing a complementary ACGT
sequence at the end of each strand (Additional file 1:
Figure S1) [11]. We investigated whether XL-DNA and
XS-DNA have immunostimulatory activity and attempted
to find possible pharmaceutical applications for cancer
immunotherapy. Both XS-DNA and XL-DNA induced
the production of immune cytokines and co-stimulatory
molecules in dendritic cells, and the XL-DNA was more
potent. XL-DNA treatment of dendritic cells in culture
and to mice via intravenous injection led to the differenti-
ation of naïve CD4+ T cells to TH1 cells. Combination
therapy with XL-DNA greatly enhanced the anti-cancer
efficacy of doxorubicin in a mouse model of colitis-
associated colon cancer. The immunostimulatory activity
of XL-DNA was mediated through TLR9 and inflamma-
somes. The results indicate a promising role for X-DNA
as an immune activator in cancer immunotherapy.
Results
X-DNA induces the activation of bone marrow-derived
primary dendritic cells
To investigate the immunostimulatory potential of X-
DNA, we examined whether XL-DNA and XS-DNA
could induce the activation of dendritic cells that are the
representative innate immune cells. The phosphorylation
of p38, ERK, JNK, and IκBα was induced by XL-DNA, a
ligated complex form of X-DNA, in bone marrow-
derived primary dendritic cells (BMDCs) (Figure 1A)
showing that XL-DNA activated MAPKs and NF-κB
pathways. Similarly, XS-DNA was also able to induce the
phosphorylation of p38, ERK, JNK, and IκBα in BMDCs
(Figure 1A). XL-DNA or XS-DNA treatment increased
mRNA levels of IL-12, TNF-α, and IFN-β in time- and
dose-dependent manners in dendritic cells (Figure 1B
Figure 1 XL-DNA and XS-DNA induce the activation of MAPKs and NF-κB and increase cytokine mRNA levels in bone marrow-derived primary
dendritic cells. A. BMDCs were treated with XL-DNA (1 μM) or XS-DNA (1 μM) for the indicated time periods. Cell lysates were analyzed by
immunoblotting. B, C. BMDCs were treated with (B) XL-DNA or XS-DNA at the indicated concentrations for 4 h or (C) 1 μM of XL-DNA or XS-DNA
for the indicated time periods. Cytokine mRNA levels were measured by quantitative real time-PCR analysis and normalized with β-actin. The mRNA
level of each cytokine was expressed as fold induction compared with control. Values are mean ± SEM (n = 3). *, Significantly different from
control (p < 0.05). Representative data from three independent experiments are presented.
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also increased by XL-DNA or XS-DNA in dendritic cells
(Figure 2A). In addition, co-stimulatory molecules such
as CD80 and CD86 were upregulated by XL-DNA or XS-
DNA treatment (Figure 2B). Overall, the potency in
immune-stimulation was greater with XL-DNA than
with XS-DNA.
These results demonstrate that XL-DNA and XS-DNA
stimulated immune activity in dendritic cells, inducing
the expression of immune-cytokines and co-stimulatory
molecules.Figure 2 XL-DNA and XS-DNA induce the expression of cytokines and co
A. BMDCs were treated with XL-DNA or XS-DNA at the indicated concent
cytokine by ELISA. B. After BMDCs were stimulated with XL-DNA or XS-DN
by flow cytometry. Values are mean ± SEM (n = 3). *, Significantly differen
experiments are presented.Activation of dendritic cells by X-DNA results in activation
of a TH1 response
Co-stimulatory molecules expressed on antigen-presenting
cells prompt the differentiation of CD4+ T cells. In particu-
lar, IL-12 skews the differentiation of naïve CD4+ T cells to
a TH1-cell lineage. Therefore, we investigated whether den-
dritic cells activated by XL-DNA were able to differentiate
naïve CD4+ T cells to TH1 effector cells. After BMDCs
were treated with ovalbumin peptide (323-339) in the pres-
ence of XL-DNA, the cells were co-cultured with naïve
CD4+ T cells for 5 days. The protein levels of IFN-γ and-stimulatory proteins in bone marrow-derived primary dendritic cells.
rations for 18 h. Culture media were collected and analyzed for each
A for 24 h, the surface expression of CD80 and CD86 was analyzed
t from control (p < 0.05). Representative data from three independent
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secretion of IFN-γ, which is a surrogate marker for TH1
cell differentiation, was up-regulated by BMDCs treated
with XL-DNA (Figure 3A) indicating the differentiation of
naïve CD4+ T cells to TH1 cells. Addition of more dendritic
cells resulted in higher production of IFN-γ, indicating the
dependency of IFN-γ production by T cells on dendritic
cells. However, the production of IL-4, which is the hall-
mark of TH2 cell differentiation, was not evident (data
not shown). The levels of IL-12 were consistently ele-
vated in both dendritic cells alone and dendritic cells
plus naïve CD4+ T cells in an XL-DNA dose-dependent
manner (Figure 3B), confirming IL-12 production by
dendritic cells in this co-incubation system.
We further investigated whether XL-DNA induced
TH1 differentiation in vivo. XL-DNA was given via intra-
peritoneal injection to mice. Blood levels of IFN-γ and
IL-12 were enhanced by XL-DNA injection (Figure 4A
and B), demonstrating the activation of TH1 cells and
dendritic cells, respectively. The observed potency to in-
crease IFN-γ and IL-12 was comparable with that of
ODN1668, a well-known immunostimulatory oligo-
nucleotide. The results suggest that XL-DNA has in vivo
immunostimulatory activities to activate innate immune
cells to produce IL-12 and to differentiate naïve CD4+ T
cells to TH1 cells.
XL-DNA enhances the efficacy of anti-cancer drug therapy
An enhanced host immune response would be beneficial
for elimination of tumor cells. Therefore, the use of im-
mune adjuvants that promote TH1 cell responses offers
an efficient strategy for anti-cancer therapy. Since XL-
DNA has immunostimulatory activity, we examined
whether XL-DNA could be applied to anti-cancer thera-
peutics using a mouse colitis-associated colorectal can-
cer model with doxorubicin as the anti-cancer drug.
Dextran sulfate sodium treatment in combination with
azoxymethane injection resulted in an incidence of co-
lonic polyps formation of more than 83% (10 of 12 mice)Figure 3 Dendritic cells activated by XL-DNA induce the differentiation of
ovalbumin peptide (323-339) (5 μg/ml) in the presence of XL-DNA with indica
cells for 5 days. Levels of (A) IFN-γ and (B) IL-12 p40 in culture supernatants w
different from XL-DNA untreated group (p < 0.05). Representative data from th
dendritic cells.(Figure 5A). Doxorubicin with or without XL-DNA was
intravenously injected six times from the eighth to the
tenth week, and the body weights of mice were moni-
tored. Overall, doxorubicin-treated mice showed a slight
decrease in body weight during the therapeutic period
(Figure 5B). Tumors were formed in the colons of
AOM/DSS-treated mice (Figure 5C). While 1 mg/kg of
doxorubicin was not sufficient to abolish tumor forma-
tion induced by AOM/DSS treatment, tumor formation
was not observed in mice treated with a combination
therapy of 1 mg/kg doxorubicin with 2.5 or 5 mg/kg XL-
DNA (Figure 5C). The therapeutic potency of 1 mg/kg
doxorubicin was greatly enhanced by combination with
XL-DNA, with an efficacy similar to twice the dosage of
doxorubicin (Figure 5C). Histological assessments consist-
ently showed that XL-DNA increased the therapeutic effi-
cacy of doxorubicin (Figure 5D). In particular, the number
of polyps greater than 3 mm size was significantly reduced
by co-treatment with XL-DNA (Figure 5E). These results
suggest the beneficial application of XL-DNA to enhance
the therapeutic efficacy of anti-cancer drugs.
Endocytosis of XL-DNA is required for its
immunostimulatory activity
To investigate the mechanism behind the immunostimula-
tory action of XL-DNA, we examined whether endocytosis
of XL-DNA was required to induce an immune response
in dendritic cells. We treated BMDCs with an endocytosis
inhibitor, dynasore, prior to XL-DNA treatment. The in-
duction of mRNA expression of IL-12 and TNF-α by XL-
DNA was significantly inhibited by dynasore (Figure 6A).
In addition, protein levels of IL-12 and TNF-α elevated by
XL-DNA were reduced by dynasore (Figure 6B). We also
tested whether endosomal acidification was necessary for
the immune activity of XL-DNA. Bafilomycin A1 sup-
pressed the expression of IL-12 and TNF-α mRNA and
proteins increased by XL-DNA in dendritic cells (Figure 6C
and D). These results show that XL-DNA is endocytosed
by immune cells to exhibit immunostimulatory activities.naïve CD4+ T cells to TH1- effector cells. BMDCs were treated with
ted concentrations for 24 h, then further co-cultured with naïve CD4+ T
ere measured by ELISA. Values are mean ± SEM (n = 3). *, Significantly
ree independent experiments are presented. N.D., not detected. DC,
Figure 4 XL-DNA induced TH1 differentiation in vivo. XL-DNA (20 nmole) or ODN1668 (20 nmole) was given via intraperitoneal injection to mice.
After 3 h, serum was obtained. The serum concentrations of (A) IFN-γ and (B) IL-12 p40 were determined by ELISA. Values are mean ± SEM
(n = 4). *, Significantly different from vehicle (p < 0.05). Representative data from two independent experiments are presented. Veh, vehicle.
Figure 5 XL-DNA enhances anti-cancer efficacy of doxorubicin in the AOM/DSS-induced colonic cancer model. A. Two cycles of dextran sodium
sulfate (DSS) treatment in combination with azoxymethane (AOM) resulted in more than 83% incidence of colonic neoplasms that were most
frequently observed in the middle and distal colon. Eight weeks after AOM injection, doxorubicin (Dox, 1 or 2 mg/kg) and/or XL-DNA (2.5 or
5 mg/kg) were i.v injected. Each group had twelve mice except for the normal control group, which had ten mice. B. Changes in mouse body
weight were monitored. C-E. Colons were obtained 15 weeks after AOM injection. C. Macroscopic features of colon. D. H&E staining of colon
sections. Arrow indicates tumor. Magnification: 40x. E. The number of colonic polyps ≥3 mm or <3 mm in size (n = 8). The incidence of colonic polyp
formation was zero in the normal control group (not shown in figure). Values are mean ± SEM (n = 8). *, Significantly different from AOM/DSS alone
group (p < 0.05). N.S., not significant from AOM/DSS alone group. Veh, vehicle.
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Figure 6 Activation of dendritic cells by XL-DNA is mediated through the endocytosis pathway. A, B. BMDCs were pre-treated with dynasore
(40 μM) for 30 min and then treated with XL-DNA for (A) 4 h or (B) 18 h. C, D. BMDCs were pre-treated with bafilomycin A1 (10 nM) for 30 min
and then treated with XL-DNA for 4 h (C) or 18 h (D). For A and C, mRNA levels were determined by quantitative real time-PCR. For B and D,
concentrations of IL-12 p40 and TNF-α were measured by ELISA. Values are mean ± SEM (n = 3). *, p < 0.05. Representative data from three
independent experiments are presented.
Koo et al. Molecular Cancer  (2015) 14:104 Page 6 of 12Immunostimulatory activity of XL-DNA is mediated
through TLR9
TLR9 is expressed in the endoplasmic reticulum under
basal conditions and traffics to the endosomal compart-
ment, where it recognizes endocytosed nucleic acids
[19]. Since endocytosis was required for XL-DNA-me-
diated immunostimulatory activity, we investigated
whether XL-DNA was able to activate TLR9. As a gain-of-
function study, HEK293T cells were transfected with
TLR9-expressing plasmid together with the NF-κB-
luciferase reporter gene, and then treated with XL-DNA at
the indicated concentrations. Overexpression of TLR9
conferred the responsiveness of cells to XL-DNA, leading
to an increase in NF-κB-dependent luciferase activity
(Figure 7A).
To confirm that immune cell activation by XL-DNA
was mediated through TLR9, we examined the activity
of XL-DNA in dendritic cells isolated from TLR9-
deficient mice. XL-DNA lost its ability to induce phos-
phorylation of MAPKs such as ERK, JNK, and p38 in
addition to phosphorylation of IκBα in TLR9-deficient
dendritic cells (Figure 7B). XL-DNA-induced production
of cytokines IL-12 and TNF-α was abolished in TLR9-
deficient dendritic cells at both the mRNA and protein
levels (Figure 7C and D). R848, a TLR7 ligand, was used
as a negative control and CpG1668, a synthetic ligand of
TLR9, was used as a positive control (Figure 7B, C, and
D). Similarly, XS-DNA-induced production of IL-12 andTNF-α was abolished in TLR9-deficient dendritic cells at
both the mRNA and protein levels (Additional file 2:
Figure S2A and B).
To confirm whether XL-DNA directly bound to TLR9,
an in vitro binding assay was performed. Myc/His-tagged
TLR9 was expressed in HEK293T cells (Figure 7E, left
panel). The cell lysates were incubated with biotin-XL-
DNA and immunoprecipitated with NA beads followed by
immunoblotting to detect TLR9 co-precipitated with XL-
DNA (Figure 7E, right panel). TLR9 was co-precipitated
with XL-DNA in an XL-DNA dose-dependent manner
(Figure 7E, right panel) showing the direct association of
XL-DNA and TLR9.
These results show that XL-DNA associates with TLR9,
thereby exerting immunostimulatory activities.
X-DNA activates a cytosolic inflammasome complex
Recently, cytosolic PRRs have emerged as targets of im-
mune therapy. Among them, the NOD-like receptor
family-dependent caspase-1 activation complex, a so
called inflammasome, recognizes infectious bacteria or
endogenous stimulatory substances in the cytosolic re-
gion and forms a caspase-1 activating platform to se-
cret mature IL-1β. Therefore, we investigated if X-DNA
had the ability to activate the inflammasome complex.
XL-DNA or XS-DNA was transfected to BMDCs to be
introduced into the cytosol. Inflammasome activation
was assessed by secretion of caspase-1 p10 and cleaved
Figure 7 XL-DNA activates TLR9. A. After HEK293T cells were transfected with NF-κB-luc and pMSCVpuro-mTLR9-Myc-expressing plasmid, cells
were treated with XL-DNA. Cell lysates were assayed for luciferase activities. Values are mean ± SEM (n = 3). *, p < 0.05. Representative data from
three independent experiments are presented. B. BMDCs isolated from wild-type (WT) or TLR9-knockout (KO) mice were treated with XL-DNA
(1 μM), R848 (100 ng/ml), or ODN1668 (ODN; 1 μM). Cell lysates were analyzed for immunoblotting. C, D. BMDCs from WT or TLR9KO mice were
treated with XL-DNA (1 μM), R848 (100 ng/ml), or ODN1668 (ODN; 1 μM) for (C) 4 h and (D) 18 h. For C, mRNA levels were determined by
quantitative real time-PCR. For D, concentrations of cytokines were measured by ELISA. For A, C, and D, values are mean ± SEM (n = 3). *, p < 0.05.
E. Whole cell lysates were obtained from HEK293T cells transfected with mTLR9-Myc/His-expressing plasmid or empty vector and were incubated with
biotinylated XL-DNA for 4 h followed by incubation with NA-beads for 2 h. Co-precipitated proteins were analyzed by immunoblotting with anti-Myc
antibody. For B-E, representative data from two independent experiments are presented. Veh, vehicle.
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ELISA. Poly dA:dT was used as a positive control as it
is well known to activate the inflammasome complex
when transfected. Both XL-DNA and XS-DNA induced
secretion of caspase-1 p10 and cleaved IL-1β in a dose-
dependent manner, with XL-DNA being more potent
(Figure 8A). Stimulation of IL-1β secretion by XL-DNA
and XS-DNA was confirmed by ELISA (Figure 8B). To
further confirm the activation of the inflammasome
complex by X-DNA, we investigated whether inflamma-
some activation induced by X-DNA was dependent on
caspase-1 using caspase-1-deficient BMDCs. Secretion of
caspase-1 p10 and cleaved IL-1β induced by XL-DNA or
XS-DNA was abolished in caspase-1-deficient dendritic
cells, as shown by immunoblotting (Figure 8C). Secretion
of IL-1β by XL-DNA or XS-DNA was completely abolishedin caspase-1-deficient dendritic cells as determined by
ELISA (Figure 8D). Poly dA:dT and ATP were positive
controls to activate the inflammasome complex mediated
through caspase-1 activation.
LRRFIP1 has been suggested as another cytosolic
nucleic acid sensor, and so we investigated whether X-
DNA could activate LRRFIP1. As a gain-of-function
study, HEK293T cells were first transfected with
LRRFIP1-expressing plasmid together with IFN-β-
promoter reporter gene, then transfected with XL-
DNA or poly dA:dT as a positive control. Transfection
with poly dA:dT induced IFN-β expression, as IFN-β-
promoter-dependent luciferase expression was in-
creased. However, transfection with XL-DNA did not
increase IFN-β-promoter-dependent luciferase activity
(Additional file 3: Figure S3).
Figure 8 XL-DNA and XS-DNA induce inflammasome activation. A, B. After BMDCs were primed with LPS (10 ng/ml, 18 h), cells were transfected
with XL- DNA, XS-DNA, or poly dA:dT for (A) 6 h or (B) 18 h. C, D. After BMDCs from wild-type (WT) or caspase-1-knockout (Casp1KO) mice were
primed with LPS (10 ng/ml, 18 h), cells were transfected with X-DNA (2 μg) or poly dA:dT (1 μg) for (C) 6 h or (D) 18 h. ATP (5 mM) was added to
dendritic cells primed with LPS for 1 h (C) or 18 h (D). For A and C, supernatant proteins and whole cell lysates (WCL) were loaded on gels and
subjected to SDS-PAGE. For B and D, concentration of IL-1β was measured by ELISA. Values are mean ± SEM (n = 3). *, p < 0.05. Representative
data from three independent experiments are presented.
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pro-caspase-1 degradation to caspase-1 and pro-IL-1β
cleavage to IL-1β when introduced into the cytosol,
suggesting that both are able to activate the cytosolic
inflammasome complex.
Collectively, our results demonstrate that X-shaped
DNAs have immunostimulatory activity resulting in the
production of immune cytokines, including IL-12, TNF-
α, and IL-1β, in dendritic cells, acting as a dual activator
of TLR9 and the inflammasome complex. X-shapedDNA represents a promising immune adjuvant to en-
hance the therapeutic efficacy of anti-cancer drugs.
Discussion
We found that X-shaped double-stranded oligonucleotides
(X-DNA) induced the activation of MAPKs and NF-κB and
the expression of immune cytokines and co-stimulatory
molecules in BMDCs, culminating in elevated TH1 cells
activity. XL-DNA forms a complex structure through the
use of a complementary sequence at each strand that
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(XL-DNA) was more potent than single unit X-DNA
(XS-DNA). Although the recognition of DNA by TLR9
is generally assumed, we explicitly demonstrated that
the immunostimulatory activity of X-DNA was mediated
through TLR9 by both gain-of-function and loss-of-
function studies. We first demonstrated that X-shaped
DNA directly associates with TLR9. The involvement of
TLR9 in X-DNA-mediated immunostimulatory activity
was further confirmed with TLR9-knockout dendritic
cells. Interestingly, our results revealed that intracellular
transfection of X-DNA culminated in the activation of the
inflammasome complex in a caspase-1-dependent man-
ner. These indicate a novel aspect of X-shaped DNA as a
dual activator for TLR9 and inflammasomes. It has been
reported that inflammasome activation in dendritic cells is
critical in anti-cancer chemotherapy by linking the innate
and adaptive immune responses against dying tumor cells
[20]. This report showed that the lack of inflammasome
components such as NLRP3 and caspase-1 results in failed
activation of IFN-γ-producing CD8+ T cells, indicating
that inflammasome activation makes anti-cancer chemo-
therapy against tumors more efficient. Therefore, the acti-
vation of inflammasomes by our X-DNA in dendritic cells
offers an additional advantage for anti-cancer therapy
compared with a single activator for TLR9.
We propose the possible therapeutic application of
XL-DNA for anti-tumor immunotherapy, since com-
bined therapy with XL-DNA enhanced the anti-tumor
activity of doxorubicin in colitis-associated colon cancer
progression. The anti-tumor activity of CpG-DNA has
previously been shown in a mouse allograft model [18].
However, to our knowledge, this is the first study to
demonstrate the anti-tumor efficacy of XL-DNA using a
more spontaneously developed cancer model. In the future
study, it would be beneficial to examine the therapeutic
efficacy of XL-DNA in the patient-derived tumor
models for preclinical and clinical applications [21].
Cancer treatment may include radiation, chemotherapy,
and surgery. However, chemotherapy and radiation nega-
tively affect normal cells. In particular, chemotherapy has
dose-limiting toxic effects on cells of the immune system,
which eventually leads to substantial morbidity and mor-
tality in cancer patients [22]. The cancer immunoediting
hypothesis in developing tumors, allowing evasion of host
immune surveillance, has been proposed [23]. Cancer
immunoediting processes consist of three distinct phases:
elimination, equilibrium, and escape. Innate immune
activity to block cancer progression disappears at the
equilibrium phase and adaptive immune activity dimin-
ishes at the escape phase. Therefore, if immune activities
can be up-regulated and maintained by immune adjuvants
in cancer patients, cancer progression may be delayed.
Combined therapeutic strategies designed to reactivate thepatient’s own immune system to fight the tumor have
been extensively pursued. As immune adjuvants for ac-
tivation of innate and adaptive immune reactions, TLR
agonists have come into the spotlight. A TLR9 agonist
enhanced antitumor T-cell responses when used as an
adjuvant for anti-cancer therapy [14]. A TLR7/8 agonist
may improve cancer immunotherapy by inducing the
differentiation of myeloid-derived suppressor cells, which
accumulate in cancer patients and suppress the host im-
mune system, into macrophages and dendritic cells [24].
In fact, several TLR agonists have been being developed as
anti-cancer drugs in clinical trials. A TLR9 agonist of the
CpG-ODN B type is being evaluated in clinical trials in
patients with melanoma and lymphoma [25,26]. Our X-
DNA effectively induced both innate and adaptive
immune responses. X-DNA induced the activation of
antigen presenting cells such as DCs to express IL-12
and co-stimulatory molecules and the differentiation of
CD4+ T cells to TH1 cells to produce IFN-γ. The activa-
tion of TH1 cells by X-DNA was confirmed by both
in vitro co-culture of CD4+ T cells and dendritic cells
and in vivo injection into mice. Furthermore, inflamma-
somes were also activated by X-DNA to secrete IL-1β.
These results suggest that X-DNA is an excellent immune
adjuvant that can be used in combination therapy with
anti-cancer drugs, reducing the required dosage of
doxorubicin and thereby possibly alleviating side effects
of anti-cancer drugs. Our results indicate a promising
new candidate of an immune adjuvant for anti-cancer
immunotherapy, especially for colon cancer.
Conclusions
XL-DNA and XS-DNA had immunostimulatory activity
via the dual activation of TLR9 and inflammasomes in
dendritic cells, leading to T cell activation. XL-DNA was
effective as an immune adjuvant, enhancing the therapeutic
efficacy of an anti-cancer drug in a colitis-associated colon
cancer animal model.
Methods
Animals and cell culture
Animal care and the study protocols were carried out in
accordance with the guidelines of the Institutional Animal
Care and Use Committee (IACUC) of the Catholic Uni-
versity of Korea (permission # 2012-5-001). C57BL/6 and
Balb/C mice were purchased from Orient Bio (Seoul,
Korea) and were acclimated under specific pathogen-free
conditions in an animal facility for at least a week before
experiments. The mice were housed in a temperature
(23 ± 3°C) and relative humidity (40-60%)-controlled
room. Balb/C TLR9 knockout (KO) mice were obtained
from Hyung-Joo Kwon (Hallym University, Gangwon-do,
Korea). C57BL/6 caspase-1KO mice were purchased from
the Jackson Laboratory (Bar Harbor, ME, USA).
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marrow cells were isolated from mice and cultured in
RPMI1640 medium containing 10% (v/v) heat-inactivated
fetal bovine serum (Life Technologies; Grand Island, NY,
USA), 50 μM of 2-mercaptoethanol, 100 units/ml of peni-
cillin, 100 μg/ml of streptomycin, 2 mM of glutamine, and
3% J558L hybridoma cell culture supernatant containing
granulocyte-macrophage colony-stimulating factor (GM-
CSF) for 6 days. Non-adherent cells were used as dendritic
cells (DCs) [27].
HEK293T cells (human embryonic kidney cells) were
cultured in Dulbecco’s modified eagle medium supple-
mented with 10% fetal bovine serum, 100 units/ml of
penicillin, and 100 μg/ml of streptomycin. Cells were
maintained at 37°C in a 5% CO2/air environment [28].
Reagents
X-shape double-stranded oligodeoxynucleotides (X-DNA)
were prepared as described previously [11]. XL-DNA re-
fers to X-DNA forming a ligated complex through self-
ligation due to ACGT sequences at the end of the strands,
while XS-DNA refers to X-DNA existing as a single mod-
ule due to the lack of sticky ACGT sequences. Sequences
of X-DNAs are shown in Additional file 1: Figure S1.
ODN1668 was purchased from TIB MOLBIOL (Berlin,
Germany). R848 was purchased from Enzo Life Sciences
(Farmingdale, NY, USA). Poly dA:dT and dynasore were
obtained from Sigma Aldrich (St. Louis, MO, USA).
Bafilomycin A1 was purchased from EMD Millipore
(Billerica, MA, USA). ATP was purchased from InvivoGen
(San Diego, CA, USA). Ovalbumin (323-339) peptide was
purchased from AnaSpec (San Jose, CA, USA).
Immunoblotting
Immunoblotting was performed using SDS-PAGE as pre-
viously described [29]. Antibodies against phospho-ERK,
phospho-JNK, phospho-p38, phospho-IκBα, ERK, JNK,
p38, and actin were purchased from Cell Signaling Tech-
nology (Boston, MA, USA). Antibody against capase-1
was obtained from Santa Cruz Biotechnology (Dallas, TX,
USA). Antibody against IL-1β was purchased from R&D
Systems (Minneapolis, MN, USA)
Reverse transcription (RT) and quantitative PCR analysis
PCR was performed as previously described [30]. Total
RNAs were isolated with Welprep™ reagent (Jeil Bio-
techservices Inc., Daegu, Korea). RNAs were reverse-
transcribed with ImProm-II™ Reverse Transcriptase
(Promega, Madison, WI, USA) and amplified with IQ™
SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA)
using an IQ™5 (Bio-Rad) for quantitative real-time PCR.
The primers were: Il-12, 5′-GAAGTTCAACATCAAG
AGCAGTAG-3′ and 5′-AGGGAGAAGTAGGAATGG
GG-3′; Tnf-α, 5′-AAAATTCGAGTGACAAGCCTGTAG-3′ and 5′-CCCTTGAAGAGAACCTGGGAGTAG-3′;
Ifn-β, 5′-TCCAAGAAAGGACGAACATTCG-3′ and 5′-T
GAGGACATCTCCCACGTCAA-3′; β-actin, 5′-TCATGA
AGTGTGACGTTGACATCCGT-3′ and 5′-TTGCGGTG
CACGATGGAGGGGCCGGA-3′. The specificity of the
amplified PCR products was assessed by a melting curve
analysis. Fold-induction of gene expression was calculated
after mRNA levels of each target gene were normalized to
β-actin levels in corresponding samples.
Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed as previously described [31]. Con-
centrations of IL-12 p40 (eBioscience Inc., San Diego, CA,
USA), TNF-α (R&D Systems), IFN-γ (eBioscience Inc.),
and IL-1β (R&D Systems) in the culture supernatants were
determined by ELISA according to the manufacturer’s in-
structions. Plates were read at 450 nm wavelength with a
microplate reader (Molecular Devices, San Francisco, CA,
USA). The concentration ranges of the standard curves
were 19.5 to 20,000, 9.7 to 10,000, 31.25 to 4,000, and
31.25 to 2,000 pg/ml for IL-12 p40, TNF-α, IFN-γ, and IL-
1β, respectively. Samples were properly diluted to be mea-
sured within the standard curve ranges.
Flow cytometric analysis
After BMDCs were treated with X-DNAs or CpG 1668
for 24 h, CD80 and CD86 surface molecules were
stained with FITC-conjugated anti-mouse antibodies
against CD80 and CD86 (BD Pharmingen, San Jose, CA,
USA) for 3 h at 4°C. After washing with staining buffer
(BD Pharmingen), cells were analyzed by FACSCanto
flow cytometer (BD Biosciences, San Jose, CA, USA).
Assay for T cell activation by DCs
TH cells were isolated from lymph nodes of C57BL/6 mice
using anti-mouse CD4 microbeads and MACS LS col-
umns according to the manufacturer’s protocol (Miltenyi
Biotec, Auburn, WA, USA). After BMDCs were stimu-
lated with ovalbumin (323-339) (5 μg/ml) in the presence
or absence of XL-DNA for 24 h, cells were co-cultured
with TH cells for 5 days. The concentrations of cytokines
in the culture supernatants were determined by ELISA.
In vivo immunostimulatory activity of XL-DNA
XL-DNA (20 nmol) or ODN1668 (20 nmol) was intra-
peritoneally injected into Balb/C mice. After 3 h, blood
samples were obtained by eye bleeding and the concen-
trations of cytokines were determined by ELISA.
Animal model of colitis-associated colon cancer
A colitis-associated cancer model was induced as previously
described with slight modifications [32]. Colitis-associated
cancer was induced by a single intraperitoneal injection
of a mutagenic agent, azoxymethane (AOM, 10 mg/kg;
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2 cycles of 2% dextran sulfate sodium (DSS) in drinking
water for 1 week and normal drinking water for
1 week. The mice were divided into six groups (n = 10-
12/group) and intravenously injected with doxorubicin
(1 or 2 mg/kg) with or without XL-DNA twice per week
for 3 weeks. The mice were sacrificed and their colons
were removed. The number and the size of polyps that
were 3 mm or larger were determined from each mouse.
For histological examination, colon tissues were infused
with 4% paraformaldehyde and embedded in paraffin. Sec-
tions from these samples were stained with hematoxylin
and eosin.
Transfection and luciferase assay
A NF-κB (2x)-luciferase reporter plasmid and pMSCV
puro-mTLR9-Myc-expressing plasmid for luciferase assay
were provided by Youme Kim (POSTECH, Pohang,
Korea). LRRFIP1-expressing plasmid was provided by Xue-
tao Cao (Second Military Medical University, Shanghai,
China). IFN-β-luciferase plasmid was provided by Shizuo
Akira (Osaka University, Osaka, Japan). Transfection of
plasmids and measurement of luciferase activity were as
described previously [31].
Immunoprecipitation study for XL-DNA binding to TLR9
Immunoprecipitation was performed as previously de-
scribed [33]. HEK293T cells were transfected with the
expression plasmid of pcDNA3.1-mTLR9-Myc/His. Cell
lysates were incubated with biotinylated XL-DNA for 2 h
and immunoprecipitated with NeutrAvidin(NA)-beads
(Thermo Scientific, Rockford, IL, USA) for 4 h at 4°C on
a rocker. Immune complexes were solubilized with
Laemmli sample buffer after washing three times. The
solubilized proteins were resolved on SDS-PAGE and
immunoblotting was performed. Anti-Myc antibody was
purchased from Cell Signaling Technology.
Statistical analysis
Data are expressed as mean ± SEM. Comparisons of data
between groups were examined by one-way ANOVA
followed by Tukey’s multiple range test (significant when
p < 0.05).
Additional files
Additional file 1: Figure S1. The structure and sequences of X-shaped
double-stranded DNA (X-DNA). XL-DNA forms a ligated complex due to
an ACGT sequence (bolded) at the end of the strand. XS-DNA does not
have the ACGT sequence and exists as a single module.
Additional file 2: Figure S2. XS-DNA-induced activation of dendritic
cells is TLR9-dependent. BMDCs from wild-type (WT) or TLR9-knockout
(KO) mice were treated with XS-DNA (1 μM) for (A) 4 h and (B) 18 h. For
A, mRNA levels were determined by quantitative real time-PCR. For B,
concentrations of cytokines were measured by ELISA. Values are mean ±SEM (n = 3). *, p < 0.05. Veh, vehicle. Representative data from three
independent experiments are presented.
Additional file 3: Figure S3. XL-DNA is unable to activate LRRFIP1.
HEK293T cells were transfected with pCMV-LRRFIP1-expressing plasmid, a
luciferase reporter plasmid containing IFN-β-promotor, and
β-galactosidase expression vector. Cells were transfected with XL-DNA or
poly dA:dT for 8 h. Luciferase activities were normalized by β-galactosidase
activities and are presented as fold inductions. Values are mean ± SEM
(n = 3). *, p < 0.05. Representative data from three independent experiments
are presented.
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